Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Dermatology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Hyperkalemia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperkalemia

21 trials tracked for Hyperkalemia: 14 in phase 3 or 4 and 11 with published results. The most-cited published study has 495 citations.

21Trials tracked

14Phase 3 & 4

0Recruiting

11With published results

Phase distribution

Phase 4 3 Phase 3 11 Phase 2 6 Other / NA 1

Phase 3 Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia Completed · 495 cited
Phase 3 Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. Completed · 401 cited
Phase 3 Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) Completed · 223 cited
Phase 3 Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months Completed · 63 cited
Phase 4 Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Completed · 46 cited
Phase 4 Patiromer With or Without Food for the Treatment of Hyperkalemia Completed · 46 cited

Show 15 more trials

Phase 3 Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects Completed · 46 cited
Phase 3 A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. Completed · 46 cited
Phase 3 Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia Completed · 17 cited
Phase 3 ZS Ph2/3 Dose-response Study in Japan Completed · 13 cited
Phase 3 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Completed · 3 cited
Phase 4 Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. Completed
Phase 3 Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. Completed
Phase 3 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia Completed
Phase 2 Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia Completed
Phase 2 The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Completed
Phase 2 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease Completed
Phase 2 A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 Completed
Phase 2 Evaluation of Patiromer in Heart Failure Patients Completed
Phase 2 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) Completed
N/A POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.